ClinicalTrials.gg
CompletedNCT05789732Updated Mar 31, 2023

Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones

An interventional study of Placebo and Silodosin in Lower Ureteric Stones, Medical Expulsive Therapy and Tadalafil, sponsored by Benha University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-03-31.

Sponsored by Benha University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Mar 2022, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study will compare the efficacy of silodosin, tadalafil versus silodosin plus tadalafil as Medical Expulsive Therapy (MET) for lower ureteric stones.

Read the detailed description

The global incidence of urolithiasis, a disease with a high recurrence rate, is increasing. Urolithiasis is one of the most common disorders of the urinary tract with a lifetime prevalence of up to 15% with men affected three times more than women.

Urolithiasis causes recurrent stone formers to experience a decline in quality of life, and there is an increasing socioeconomic burden associated with the management of urolithiasis. Improved quality of life may also have increased its prevalence. A significant proportion, about 1/5th of urinary tract stones, is found in the ureter, of which 2/3rd is seen in the distal ureter. Initially, a colicky pain of various grades presents with ureteric stone. It is one of the most common problems that compel a patient to an emergency room.

Methods to manage ureteral stones include conservative treatment, pharmacological treatment (e.g., medical expulsive therapy), shock wave lithotripsy, and surgical treatment. Thus, urologists must select the appropriate treatment for each patient (i.e., non-surgical or surgical). Today, medical expulsive therapy has become the most used modality of treatment for urolithiasis. During this treatment, the ureter smooth muscle is treated via various drugs by different mechanisms.

Blocking alpha-(α-) 1 adrenergic receptor, especially in the distal third decreases basal smooth muscle contraction and causes propulsive antegrade peristalsis helping stone expulsion. By increasing the intraureteral pressure gradient around the stone, alpha-1 adrenergic receptor antagonists eject distal ureteral stones.

Significant pathological changes can occur when ureteric stones are impacted. +is can cause an inflammatory reaction with mucosal edema which could further worsen the ureteric obstruction, increasing the risk of impaction and retention. However, selective alpha-1 blockers, such as tamsulosin and silodosin, have been the treatment of choice, with proven efficacy in multiple clinical trials. Silodosin is a more selective α-1A adrenoceptor blocker with a better stone expulsion rate than tamsulosin.

Recently, a newer Phosphodiesterase type 5 inhibitor, tadalafil, has shown action on the nitric oxide-cyclic guanosine monophosphate signaling pathway of smooth muscles, resulting in increased levels of cyclic guanosine monophosphate, causing ureteric relaxation.

Due to its smooth muscle relaxation mechanism, tadalafil has received US Food and Drug Administration approval to treat many urinary tract diseases. Therefore, the combination of silodosin and tadalafil drugs is aimed to facilitate stone passage by better ureteric relaxation and reducing intramural ureter pressure. Although there have been few similar studies using various combinations, comparing the efficacy of silodosin and tadalafil vs. silodosin are very few, and these studies have taken longer duration of treatment (4 to 6 weeks) which might have affected the outcome.

02

Conditions studied

  • Lower Ureteric Stones
  • Medical Expulsive Therapy
  • Tadalafil
  • Silodosin
03

In context

Lead sponsor

Benha University is the lead sponsor of 364 studies on the registry; 67 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 168 patients aged >18 years old.
  • Both sexes.
  • Diagnosed with lower ureteric stone from 5mm to 10mm in size.

Exclusion criteria

Exclusion Criteria:

  • Patients with multiple or bilateral ureteric stones
  • single kidney or impairment of renal function
  • Urinary tract infection (UTI)
  • Marked hydronephrosis
  • Patients presenting with severe intractable pain and requiring emergency intervention
  • Any urologic anomalies or history of ureteral surgery
  • Pregnancy
  • Pediatric populations
  • Ischemic heart disease
  • Congestive cardiac failure
  • Complicated hypertension
  • Patients on concomitant treatment with nitrates or calcium channel blockers.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
168 participants (actual)

Study arms

  • Placebo comparator
    Placebo group

    Patients in this group will receive placebo treatment once daily.

    Drug: Placebo

  • Experimental
    Silodosin group

    Patients will receive Silodosin 8 mg once daily.

    Drug: Silodosin

  • Experimental
    Tadalafil group

    Patients will receive Tadalafil 5 mg once daily.

    Drug: Tadalafil

  • Experimental
    Silodosin and Tadalafil

    Patients will receive Silodosin 8mg in combination with Tadalafil 5 mg once daily.

    Drug: Silodosin and Tadalafil

Interventions

  • DrugPlacebo

    Patients will receive placebo treatment once daily.

  • Patients will receive Silodosin 8 mg once daily.

  • Patients will receive Tadalafil 5 mg once daily.

  • DrugSilodosin and Tadalafil

    Drug pages: Silodosin · Tadalafil

    Patients will receive Silodosin 8mg in combination with Tadalafil 5 mg once daily.

06

What researchers measure

Primary outcomes

  1. Stone expulsion rate

    Stone expulsion rate will be recorded

    Time frame: Intraoperatively

Secondary outcomes

  1. Stone expulsion time

    Stone expulsion time will be recorded

    Time frame: Intraoperatively

  2. Amount of analgesia used

    The amount of analgesia used will be recorded

    Time frame: Intraoperatively

07

Study locations

1 site
  • Benha University Hospitals
    Benha, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — The study will be available under a reasonable request of the corresponding author

Supporting information: Study protocol

Time frame: One year after the end of the study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Aug 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
Mar 29, 2023
StartActual
Mar 30, 2022
Primary completionActual
Aug 30, 2022
CompletionActual
Aug 30, 2022
Last update
Mar 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05789732
Lead sponsor
Benha University
Responsible party
Tamer Abd El-Wahab Diab (Lecturer of Urology, Faculty of Medicine, Benha University, Benha, Egypt, Benha University) — Principal investigator
First posted
Mar 29, 2023
Start date
Mar 30, 2022
Primary completion
Aug 30, 2022
Completion
Aug 30, 2022
Last update
Mar 31, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Silodosin · Tadalafil

Start the discussion